[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Chen
Li-rong
LR
D000077384:Anastrozole; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000648:ultrastructure; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000473:pathology / Q000648:ultrastructure; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009570:Nitriles / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use; D000068878:Trastuzumab; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D009570:Nitriles; D043823:Taxoids; D014230:Triazoles; D000077384:Anastrozole; D000068878:Trastuzumab